Professional
Added to YB: 2025-07-22
Pitch date: 2025-07-18
COGT [bullish]
Cogent Biosciences, Inc.
+230.27%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Market Cap
$1.7B
Pitch Price
$12.75
Price Target
22.00 (-48%)
Dividend
N/A
EV/EBITDA
-5.76
P/E
-6.13
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
Citi Boosts Cogent Price Target to $22
COGT (analyst u/g): Citi increases PT to $22 (Buy) post-bezu SUMMIT success in NonAdvSM (+69%). Bezu viewed as Ayvakit upgrade. Catalysts: symptom/biomarker data (ASH?), APEX trial in AdvSM (2H25), PEAK trial in GIST (YE25). Market underestimating all three opportunities, creating further upside potential.
Read full article (1 min)